PAS
CORT icon

Park Avenue Securities’s Corcept Therapeutics CORT Stock Holding History

Park Avenue Securities’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
+3,449
New +$208K ﹤0.01% 1528
2025
Q2 		– Sell
-2,266
Closed -$259K – 1490
2025
Q1 		$259K Buy
+2,266
New +$138K ﹤0.01% 1049

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Avenue Securities's CORT Position: Q2 2026 in Review

Park Avenue Securities opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,449 shares worth $300K. The stake represents ﹤0.01% of the portfolio and ranks #1528 among its holdings. This is a return to the name: Park Avenue Securities previously reported a position in CORT as recently as Q1 2025.

Park Avenue Securities first reported a position in CORT in Q1 2025 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Park Avenue Securities held 3,449 shares of Corcept Therapeutics worth $300K as of Q2 2026.
  • Corcept Therapeutics was a new Park Avenue Securities position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1528 holding.
  • Park Avenue Securities first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.